DK3329909T3 - Fenfluramin til anvendelse i behandling af dravet syndrom - Google Patents
Fenfluramin til anvendelse i behandling af dravet syndrom Download PDFInfo
- Publication number
- DK3329909T3 DK3329909T3 DK18152406.7T DK18152406T DK3329909T3 DK 3329909 T3 DK3329909 T3 DK 3329909T3 DK 18152406 T DK18152406 T DK 18152406T DK 3329909 T3 DK3329909 T3 DK 3329909T3
- Authority
- DK
- Denmark
- Prior art keywords
- fenfluramine
- treatment
- syndrome
- drug
- drug syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/887,014 US9549909B2 (en) | 2013-05-03 | 2013-05-03 | Method for the treatment of dravet syndrome |
| EP14724037.8A EP2991637B1 (en) | 2013-05-03 | 2014-05-01 | Fenfluramine for use in the treatment of dravet syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3329909T3 true DK3329909T3 (da) | 2021-04-19 |
Family
ID=50729472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18152406.7T DK3329909T3 (da) | 2013-05-03 | 2014-05-01 | Fenfluramin til anvendelse i behandling af dravet syndrom |
| DK14724037.8T DK2991637T3 (da) | 2013-05-03 | 2014-05-01 | Fenfluramin til anvendelse i behandling af dravets syndrom |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14724037.8T DK2991637T3 (da) | 2013-05-03 | 2014-05-01 | Fenfluramin til anvendelse i behandling af dravets syndrom |
Country Status (17)
| Country | Link |
|---|---|
| US (12) | US9549909B2 (da) |
| EP (2) | EP3329909B1 (da) |
| JP (3) | JP6441313B2 (da) |
| AU (4) | AU2014261329B2 (da) |
| BR (1) | BR112015027282A8 (da) |
| CA (1) | CA2909335C (da) |
| CY (1) | CY1124298T1 (da) |
| DK (2) | DK3329909T3 (da) |
| ES (2) | ES2863929T3 (da) |
| HR (1) | HRP20210819T1 (da) |
| HU (1) | HUE054577T2 (da) |
| LT (1) | LT3329909T (da) |
| NO (1) | NO3092234T3 (da) |
| PL (2) | PL2991637T3 (da) |
| PT (2) | PT2991637T (da) |
| SI (1) | SI3329909T1 (da) |
| WO (1) | WO2014177676A1 (da) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| SG11201702494UA (en) | 2014-09-29 | 2017-04-27 | Zogenix Internat Ltd | Control system for control of distribution of medication |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| AU2016222804C1 (en) * | 2015-02-25 | 2021-10-14 | The Regents Of The University Of California | 5HT agonists for treating disorders |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| HRP20240508T1 (hr) * | 2015-08-24 | 2024-07-05 | Zogenix International Limited | Metode liječenja lennox-gastaut sindroma fenfluraminom |
| SG11201802870RA (en) | 2015-10-09 | 2018-05-30 | Univ Southampton | Modulation of gene expression and screening for deregulated protein expression |
| CA3005256A1 (en) | 2015-12-14 | 2017-06-22 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
| US20170174614A1 (en) | 2015-12-22 | 2017-06-22 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| KR102688278B1 (ko) | 2015-12-22 | 2024-07-26 | 조게닉스 인터내셔널 리미티드 | 펜플루라민 조성물 및 그 제조 방법 |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| RU2746000C2 (ru) * | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| US20180092864A1 (en) * | 2016-09-30 | 2018-04-05 | Zogenix International Limited | Compositions and methods for treating seizure disorders |
| AU2017363598A1 (en) * | 2016-11-22 | 2019-05-23 | Ovid Therapeutics Inc. | Methods of treating developmental disorders and/or seizure disorders with flupirtine |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| US10765646B2 (en) | 2017-04-13 | 2020-09-08 | Ovid Therapeutics Inc. | Methods of treating developmental encephalopathies |
| KR20190142364A (ko) * | 2017-05-09 | 2019-12-26 | 조게닉스 인터내셔널 리미티드 | 펜플루라민을 사용하여 두즈 증후군을 치료하는 방법 |
| SG10202108375XA (en) | 2017-08-25 | 2021-09-29 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
| WO2019067413A1 (en) * | 2017-09-26 | 2019-04-04 | Zogenix International Limited | USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| US20190091176A1 (en) * | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Method of treating selected patient population experiencing dravet syndrome |
| US20190091179A1 (en) * | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Congnitive function with fenfluramine |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| BR112020022512A2 (pt) | 2018-05-04 | 2021-05-04 | Stoke Therapeutics, Inc. | métodos e composições para tratamento de doença de armazenamento de éster de colesteril |
| WO2019216919A1 (en) * | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EP3806835A1 (en) * | 2018-06-14 | 2021-04-21 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| EP3820459A1 (en) * | 2018-07-10 | 2021-05-19 | Zogenix International Limited | Fenfluramine for use for treating epilepsy or epileptic encephalopathy in patients without pulmonary hypertension |
| KR20210061332A (ko) * | 2018-07-27 | 2021-05-27 | 제논 파마슈티칼스 인크. | 뇌전증 치료 방법 |
| EP3930841A4 (en) * | 2019-02-25 | 2022-11-30 | Zogenix International Limited | FORMULATION TO IMPROVE SEIZURE CONTROL |
| CN111944835B (zh) * | 2019-05-14 | 2022-03-29 | 南通大学 | 一种突变型gabrg2转基因斑马鱼癫痫模型的构建方法及应用 |
| EP4021454A1 (en) * | 2019-08-30 | 2022-07-06 | Research Institute at Nationwide Children's Hospital | Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction |
| WO2021053389A1 (en) | 2019-09-17 | 2021-03-25 | Zogenix International Limited | Methods of treating epileptic patients with fenfluramine |
| US20210299064A1 (en) | 2020-02-05 | 2021-09-30 | Zogenix International Limited | Method of treating patients with lennox-gastaut syndrome |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| CN115867657A (zh) | 2020-05-11 | 2023-03-28 | 斯托克制药公司 | 用于治疗疾患和疾病的opa1反义寡聚物 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1413070A (en) | 1973-07-27 | 1975-11-05 | Beecham Group Ltd | Process for the production of - norfenfluramine and - fenfluramine and salts thereof |
| GB1413078A (en) | 1973-07-27 | 1975-11-05 | Beecham Group Ltd | Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof |
| US4452815A (en) | 1980-06-16 | 1984-06-05 | Massachusetts Institute Of Technology | Method of utilizing d,l-fenfluramine for modifying feeding behavior |
| IT1238686B (it) | 1990-02-09 | 1993-09-01 | Lab Mag Spa | Procedimento per la preparazione di levo e destro fenfluramina |
| FR2684552B1 (fr) | 1991-12-06 | 1995-04-28 | Adir | Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants. |
| US5985880A (en) | 1996-06-05 | 1999-11-16 | Delta Pharmaceuticals | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
| US5834477A (en) | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
| WO2003011306A1 (en) | 2001-07-31 | 2003-02-13 | Wyeth | Sucralose formulations to mask unpleasant tastes |
| US6599901B1 (en) | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
| US7101572B2 (en) | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
| CN101257889A (zh) | 2005-05-25 | 2008-09-03 | 詹森药业有限公司 | 托吡酯的儿科制剂 |
| GB0515090D0 (en) | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
| US9125900B2 (en) | 2005-09-14 | 2015-09-08 | University Of The Witwatersrand, Johannesburg | Pharmaceutical composition |
| CA2660431C (en) | 2006-08-31 | 2015-03-17 | The Governors Of The University Of Alberta | Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators |
| JP2011507800A (ja) | 2007-12-26 | 2011-03-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト |
| CA3066426A1 (en) | 2008-01-09 | 2009-07-16 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
| BRPI0919796A2 (pt) | 2008-10-09 | 2015-12-15 | Acraf | formulação farmacêutica líquida livre de açúcar, e, excipiente líquido livre de açucar farmaceuticamente aceitável |
| EP2419400A1 (en) | 2009-04-15 | 2012-02-22 | Research Triangle Institute | Monoamine reuptake inhibitors |
| US9453027B2 (en) | 2009-07-27 | 2016-09-27 | Daljit Singh Dhanoa | Deuterium-enriched pyridinonecarboxamides and derivatives |
| WO2011085181A1 (en) | 2010-01-08 | 2011-07-14 | Eurand, Inc. | Taste masked topiramate composition and an orally disintegrating tablet comprising the same |
| US20140162942A1 (en) | 2010-07-30 | 2014-06-12 | Anima Ghosal | Inhibition of cyp3a drug metabolism |
| US20120270848A1 (en) | 2010-10-22 | 2012-10-25 | Galleon Pharmaceuticals, Inc. | Novel Compositions and Therapeutic Methods Using Same |
| JP2013540807A (ja) | 2010-10-26 | 2013-11-07 | アルファーマ ファーマシューティカルズ エルエルシー | オピオイド過量投与によって誘発される呼吸抑制を減弱する製剤および方法 |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| WO2014078575A2 (en) | 2012-11-15 | 2014-05-22 | Galleon Pharmaceuticals, Inc. | Novel orally bioavailable breathing control modulating compounds, and methods of using same |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| SI3035926T1 (sl) | 2013-08-19 | 2020-11-30 | The Regents Of The University Of California | Spojine in postopki za zdravljenje epileptičnih motenj |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| AU2016222804C1 (en) | 2015-02-25 | 2021-10-14 | The Regents Of The University Of California | 5HT agonists for treating disorders |
| KR102207539B1 (ko) | 2015-06-30 | 2021-01-26 | 네우라드 리미티드 | 신규한 호흡 제어 조절 화합물, 및 그의 제조 및 사용 방법 |
| US10004749B2 (en) | 2015-07-22 | 2018-06-26 | John Hsu | Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof |
| HRP20240508T1 (hr) | 2015-08-24 | 2024-07-05 | Zogenix International Limited | Metode liječenja lennox-gastaut sindroma fenfluraminom |
| US20170071949A1 (en) | 2015-09-14 | 2017-03-16 | Zogenix International Limited | Combination treatment of specific forms of epilepsy |
| KR102688278B1 (ko) | 2015-12-22 | 2024-07-26 | 조게닉스 인터내셔널 리미티드 | 펜플루라민 조성물 및 그 제조 방법 |
| RU2746000C2 (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| US20180092864A1 (en) | 2016-09-30 | 2018-04-05 | Zogenix International Limited | Compositions and methods for treating seizure disorders |
| KR20190142364A (ko) | 2017-05-09 | 2019-12-26 | 조게닉스 인터내셔널 리미티드 | 펜플루라민을 사용하여 두즈 증후군을 치료하는 방법 |
-
2013
- 2013-05-03 US US13/887,014 patent/US9549909B2/en active Active
-
2014
- 2014-05-01 SI SI201431811T patent/SI3329909T1/sl unknown
- 2014-05-01 CA CA2909335A patent/CA2909335C/en active Active
- 2014-05-01 ES ES18152406T patent/ES2863929T3/es active Active
- 2014-05-01 BR BR112015027282A patent/BR112015027282A8/pt not_active Application Discontinuation
- 2014-05-01 DK DK18152406.7T patent/DK3329909T3/da active
- 2014-05-01 PL PL14724037T patent/PL2991637T3/pl unknown
- 2014-05-01 PL PL18152406T patent/PL3329909T3/pl unknown
- 2014-05-01 PT PT147240378T patent/PT2991637T/pt unknown
- 2014-05-01 LT LTEP18152406.7T patent/LT3329909T/lt unknown
- 2014-05-01 JP JP2016511083A patent/JP6441313B2/ja active Active
- 2014-05-01 PT PT181524067T patent/PT3329909T/pt unknown
- 2014-05-01 EP EP18152406.7A patent/EP3329909B1/en active Active
- 2014-05-01 WO PCT/EP2014/058954 patent/WO2014177676A1/en active Application Filing
- 2014-05-01 DK DK14724037.8T patent/DK2991637T3/da active
- 2014-05-01 HU HUE18152406A patent/HUE054577T2/hu unknown
- 2014-05-01 AU AU2014261329A patent/AU2014261329B2/en active Active
- 2014-05-01 ES ES14724037.8T patent/ES2666657T3/es active Active
- 2014-05-01 EP EP14724037.8A patent/EP2991637B1/en not_active Revoked
- 2014-07-30 US US14/447,369 patent/US20140343044A1/en not_active Abandoned
- 2014-07-30 US US14/447,303 patent/US9603814B2/en active Active
- 2014-07-30 US US14/447,253 patent/US9610260B2/en active Active
- 2014-12-03 NO NO14819206A patent/NO3092234T3/no unknown
-
2016
- 2016-01-21 US US15/003,161 patent/US9603815B2/en active Active
-
2017
- 2017-02-10 US US15/429,506 patent/US20170151259A1/en not_active Abandoned
- 2017-02-10 US US15/429,650 patent/US20170151194A1/en not_active Abandoned
- 2017-02-10 US US15/429,641 patent/US20170151257A1/en not_active Abandoned
- 2017-02-10 US US15/429,646 patent/US10478442B2/en active Active
- 2017-02-10 US US15/429,516 patent/US10478441B2/en active Active
-
2018
- 2018-11-21 JP JP2018218149A patent/JP6655156B2/ja active Active
-
2019
- 2019-05-16 AU AU2019203448A patent/AU2019203448B2/en active Active
- 2019-05-31 AU AU2019203832A patent/AU2019203832B2/en active Active
- 2019-10-08 US US16/596,166 patent/US20200030341A1/en not_active Abandoned
-
2020
- 2020-01-31 JP JP2020014754A patent/JP6966584B2/ja active Active
- 2020-06-12 US US16/900,055 patent/US20210121479A1/en not_active Abandoned
- 2020-11-12 AU AU2020267264A patent/AU2020267264A1/en not_active Abandoned
-
2021
- 2021-05-21 HR HRP20210819TT patent/HRP20210819T1/hr unknown
- 2021-06-14 CY CY20211100530T patent/CY1124298T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3329909T3 (da) | Fenfluramin til anvendelse i behandling af dravet syndrom | |
| DK3030262T3 (da) | Kombineret farmaceutisk sammensætning | |
| DK3121164T3 (da) | Sulfamoylpyrrolamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b | |
| DK2968208T3 (da) | Behandling af kataplexi | |
| DK3329884T3 (da) | Implanterbar indretning til behandling af glaukom | |
| BR112016005121A2 (pt) | Artigo absorvente | |
| DK2906698T3 (da) | Fremgangsmåde til behandling af alports syndrom | |
| BR112016003758A2 (pt) | Artigo absorvente | |
| DK3054976T3 (da) | Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose | |
| DK2861273T3 (da) | Anvendelse af heparin og kulhydrater til behandling af cancer. | |
| DK2764881T3 (da) | System til medicinsk behandling | |
| UY4332S (es) | Soporte | |
| DK3391902T3 (da) | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati | |
| DK2777689T3 (da) | Ny farmaceutisk sammensætning til behandling af svampeinfektioner | |
| DK2688588T3 (da) | Hurtig- og langtidsvirkende immunologisk terapeutisk middel | |
| DK3044229T3 (da) | Peptider til anvendelse i behandlingen af oral mucositis | |
| FI20135231A (fi) | Potilasalusta | |
| FI20125937A (fi) | Järjestely ja menetelmä rakenneosan kannattamiseksi | |
| ES2717446T3 (es) | Péptidos derivados de ERK y usos de los mismos | |
| DK3071192T3 (da) | Curcuphenolforbindelse til anvendelse i behandling af cancer | |
| DK2976101T3 (da) | Behandlingsfremgangsmåde | |
| BR112016008035A2 (pt) | composição, uso da composição | |
| FR3007291B1 (fr) | Composition cicatrisante et utlisation | |
| DK2976089T3 (da) | Anvendelse af sedoheptulose til forebyggelse eller behandling af inflammation | |
| DE112013007428A5 (de) | Komponententräger |